Matinas BioPharma Holdings Inc
MTNB0.692USD
+0.022+3.24%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.08MMarket Cap
LossP/E TTM
More Details of Matinas BioPharma Holdings Inc Company
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Matinas BioPharma Holdings Inc Info
Ticker SymbolMTNB
Company nameMatinas BioPharma Holdings Inc
IPO dateJun 03, 2014
CEOJabbour (Jerome D)
Number of employees3
Security typeOrdinary Share
Fiscal year-endJun 03
AddressSuite 302
CityBEDMINSTER
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code07921
Phone19084431860
Websitehttps://www.matinasbiopharma.com/
Ticker SymbolMTNB
IPO dateJun 03, 2014
CEOJabbour (Jerome D)
Company Executives of Matinas BioPharma Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lazar (David Elliot)
8.51%
Hezbay Holdings LLC
3.96%
Stern (Adam K.)
3.29%
Sanitam Partners LLC
3.29%
111 Equity Group LLC
2.87%
Other
78.09%
Shareholders
Shareholders
Proportion
Lazar (David Elliot)
8.51%
Hezbay Holdings LLC
3.96%
Stern (Adam K.)
3.29%
Sanitam Partners LLC
3.29%
111 Equity Group LLC
2.87%
Other
78.09%
Shareholder Types
Shareholders
Proportion
Individual Investor
11.99%
Corporation
10.12%
Investment Advisor
3.38%
Investment Advisor/Hedge Fund
1.25%
Hedge Fund
0.66%
Research Firm
0.04%
Other
72.56%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
79
289.20K
5.21%
-1.20M
2025Q2
92
935.12K
18.38%
-1.08M
2025Q1
95
951.53K
18.71%
-830.58K
2024Q4
93
476.15K
9.43%
-1.21M
2024Q3
96
1.46M
29.08%
+470.67K
2024Q2
100
917.39K
18.29%
+218.76K
2024Q1
105
652.02K
14.56%
-47.03K
2023Q4
117
656.55K
15.11%
-41.82K
2023Q3
118
657.56K
15.13%
-45.97K
2023Q2
125
652.59K
15.02%
-352.98K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lazar (David Elliot)
545.00K
9.81%
+545.00K
--
Aug 15, 2025
Stern (Adam K.)
210.69K
3.79%
--
--
Apr 08, 2025
Sanitam Partners LLC
210.69K
3.79%
+210.69K
--
May 09, 2025
111 Equity Group LLC
183.64K
3.31%
-64.36K
-25.95%
Feb 13, 2025
The Vanguard Group, Inc.
59.73K
1.08%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
55.49K
1%
+8.75K
+18.73%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
49.65K
0.89%
--
--
Jun 30, 2025
Sargent Investment Group, LLC
35.62K
0.64%
-6.18K
-14.78%
Jun 30, 2025
Holos Integrated Wealth LLC
32.48K
0.58%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Date
Type
Ratio
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
FAQs
Who are the top five shareholders of Matinas BioPharma Holdings Inc?
The top five shareholders of Matinas BioPharma Holdings Inc are:
Lazar (David Elliot) holds 545.00K shares, accounting for 9.81% of the total shares.
Stern (Adam K.) holds 210.69K shares, accounting for 3.79% of the total shares.
Sanitam Partners LLC holds 210.69K shares, accounting for 3.79% of the total shares.
111 Equity Group LLC holds 183.64K shares, accounting for 3.31% of the total shares.
The Vanguard Group, Inc. holds 59.73K shares, accounting for 1.08% of the total shares.
Lazar (David Elliot) holds 545.00K shares, accounting for 9.81% of the total shares.
Stern (Adam K.) holds 210.69K shares, accounting for 3.79% of the total shares.
Sanitam Partners LLC holds 210.69K shares, accounting for 3.79% of the total shares.
111 Equity Group LLC holds 183.64K shares, accounting for 3.31% of the total shares.
The Vanguard Group, Inc. holds 59.73K shares, accounting for 1.08% of the total shares.
What are the top three shareholder types of Matinas BioPharma Holdings Inc?
The top three shareholder types of Matinas BioPharma Holdings Inc are:
Lazar (David Elliot)
Hezbay Holdings LLC
Stern (Adam K.)
Lazar (David Elliot)
Hezbay Holdings LLC
Stern (Adam K.)
How many institutions hold shares of Matinas BioPharma Holdings Inc (MTNB)?
As of 2025Q3, 79 institutions hold shares of Matinas BioPharma Holdings Inc, with a combined market value of approximately 289.20K, accounting for 5.21% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -13.18%.
What is the biggest source of revenue for Matinas BioPharma Holdings Inc?
In --, the -- business generated the highest revenue for Matinas BioPharma Holdings Inc, amounting to -- and accounting for --% of total revenue.
